
The Bone and Mineral Manual
A Practical Guide
- 1st Edition - December 2, 2012
- Imprint: Academic Press
- Editors: Michael Kleerekoper, Ethel S. Siris, Michael McClung
- Language: English
- Paperback ISBN:9 7 8 - 0 - 1 2 - 4 1 2 6 5 0 - 3
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 1 3 7 6 6 - 9
The Bone and Mineral Manual incorporates the most up-to-date laboratory methods, techniques, and approaches for designing strategies and investigating the pathophysiology of bone a… Read more
Purchase options

- Brings together current bone and mineral metabolism methods in one easily accessible volume
- Provides a quick reference for immediate handling of bone and mineral disorders
- Presents information in bullets, highlights, tables, and decision trees rather than lengthy text
- Addresses problems likely to be seen at all ages, from pre-term infant to the centenarian
- Ideal for practicing physicians, residents and medical students
M. Kleerekoper, M. McClung, and E. Siris eds.
A. Neonates and Children
1. Neonatal Hypocalcemia (5)
Preterm Infants with Fractures and Rickets (4)
Rickets (5)
Winston Koo (Wayne State U., Detroit)
2. A Clinical Approach to Osteogenesis Imperfecta
Jay Shapiro, Rebecca Slayton, and Paul Sponsellor (Francis Scott Key Medical Center, Baltimore)
(11 slides)
B. Adolescents
3. Juvenile Osteoporosis
Pubertal problems affecting the skeleton
Reggie Tsang and Jorge Prada (U. Cincinnati)
(1 slide) originally down for 18 slides
4. Fibrous Dysplasia
Fred Kaplan (U. Penn)
(10 slides)
C. Young Adults
5. Secondary Amenorrhea
Anne Klibanski and Karen Miller (Mass General)
(6 slides)
6. Osteoporosis in Men
Eric Orwoll (VA Medical Center, Portland, OR)
(10 slides)
??? Pregnancy and Lactation in Women with known Bone/Mineral Diseases
(10 slides)
?????
7. Nephrolithiasis
Murray Favus (Univ. Chicago)
(6 slides) originally down for 20
8. Reflex Sympathetic Dystrophy
Velkjo Matkovic (Ohio State, Columbus)
(3 slides) originally down for 10-12
D. Diagnostic Procedures
9. A Practical Guide to Bone Densitometry
Dorothy Nelson and Michael Kleerekoper
(2 slides)
10. Indications for Bone Mass Measurement
Dorothy Nelson and Michael Kleerekoper
(3 slides)
11. Laboratory Analyses Useful in Diagnosis of Bone and Calcium Metablic Disorders
Hunter Heath (Eli Lilly, Indianapolis)
(10 slides)
12. Biochemical markers of bone remodeling
Mike Kleerekoper (Wayne State, Detroit)
(10 slides)
13. Skeletal Radiology
Harry Genant (UCSF)
(7 slides)
14. Scintography
Ignace Fogelman (Guy's Hospital, London)
(4 slides)
Parathyroid localization
John Doppman
DROPPED
15. Bone Biopsy, pathology, malignancy
Robert Recker (Creighton Univ., Omaha)
(6 slides)
E. Prevention/bone loss
16. Marjorie Luckey (Mt. Sinai, New York)
(20 slides)
17. Prevention of Fractures in Patients with Low Bone Mass
Susan Greenspan (Beth Israel)
(6 slides)
18. Evaluation of Osteoporosis
Michael Kleerekoper and Ethel Siris
(decision tree)
19. General Approaches/Pharmacology (MM)
Nelson Watts (Emory U., Atlanta)
(30 slides)
20. Nonpharmacologic approaches (MM)
Mike McClung (ORC, Portland, OR)
(10 slides)
F. Steroid-induced osteoporosis
21. Glucocorticoid-Induced Osteoporosis
Barbara Lukert (Univ. Kansas, Kansas City)
(10 slides)
22. High Bone Mass (MM)
Mike Whyte (Wash. U.)
(decision tree/3 slides)
23. Osteomalacia (ES)
John Haddad (Pennsyl
(decision tree/10-15 slides)
G. Hypercalcemia
24. The Non-parathyroid Chronic Hypercalcemias
Larry Mallette (Baylor U., Houston)
(15 slides)
25. Primary Hyperparathyroidism
John Bilezikian (Columbia)
(8 slides)
26. Bone Metastasis
Bob Gagel
(4 decision trees and 4 slides)
H. Hypocalcemia
27. Fred Singer (St. John's Hosp., Santa Monica)
(4 slides)
I. Paget's Disease
28. Ethel Siris (Columbia P&S, New York)
(23 slides)
J. The Renal Osteodystrophies Types and Classification
29. Jack Coburn (Los Angeles, CA)
(22 slides)
K. Osteoporosis after Organ Transplantation
30. Elizabeth Shane (Columbia P&S, New York)
(12 slides)
L. Patient and Family Education Support Groups (MM)
31. Betsy McClung (Portland, OR)
(7 slides)
Appendix - 3 pages
- Edition: 1
- Published: December 2, 2012
- Imprint: Academic Press
- Language: English
MK
Michael Kleerekoper
ES
Ethel S. Siris
Ethel S. Siris, MD, is the Madeline C. Stabile Professor of Clinical Medicine in the Department of Medicine, College of Physicians and Surgeons of Columbia University, and the Director of the Toni Stabile Osteoporosis Center of the Columbia University Medical Center, New York-Presbyterian Hospital, all in New York, New York. She is a graduate of Radcliffe College, Harvard University, and received her medical degree from the College of Physicians and Surgeons of Columbia University. An endocrinologist, she works as a clinician, as a clinical investigator and as a medical educator, all in the area of metabolic bone diseases, including osteoporosis and Paget's disease of bone. In her career she has participated in research activities with bisphosphonates, selective estrogen receptor modulators (SERMS) and RANKL inhibitors. Dr. Siris served as the Medical Director of NORA, the National Osteoporosis Risk Assessment, a public health initiative and longitudinal study of osteoporosis that included over 200,000 postmenopausal women in the US. Most recently her research activity has focused both on risk factors for osteoporosis and treatment adherence with osteoporosis medications.
Dr. Siris is the immediate past president of the National Osteoporosis Foundation and currently serves on the Board of Trustees of both the National Osteoporosis Foundation in the US and the International Osteoporosis Foundation. She is also a member and former vice chair of the Board of Directors of the Paget Foundation for Paget's Disease of Bone and Related Disorders. She has previously served on the Council of the American Society for Bone and Mineral Research and on the Endocrinologic and Metabolic Drugs Advisory Committee of the US Food and Drug Administration. She has published widely in the medical literature and is co-editor of the book, The Bone and Mineral Manual. Dr. Siris has been interviewed frequently on both television and radio and is often quoted in print media regarding osteoporosis.
MM
Michael McClung
Dr. Michael McClung is the founding director of the Oregon Osteoporosis Center. He graduated from Rice University in Houston and from the University of Texas Southwestern Medical School in Dallas. After his training in Internal Medicine at Parkland Hospital in Dallas, he completed a fellowship in Endocrinology at the National Institute of Health in Bethesda, Maryland. He then joined the faculty at the Oregon Health Sciences University, where he is an Associate Professor of Medicine. At OHSU, he founded a clinic devoted to the care of patients with disorders of bone and calcium metabolism that eventually grew into the Oregon Osteoporosis Center. In 1987, Dr. McClung joined the Department of Medical Education at Providence Medical Center where he is actively involved in the training of young physicians. He is board certified in both Internal Medicine and in Endocrinology and Metabolism, and is a fellow of the American College of Endocrinologists and the American College of Physicians.
Dr. McClung is an internationally recognized expert in the fields of osteoporosis and bone density testing. His Center has been involved in many of the important clinical studies that resulted in the availability of the medications now used to treat osteoporosis and Paget's disease of bone. He has published more than 200 papers and book chapters, is co-editor of a book for clinicians about disorders of bone and mineral metabolism and is a member of the editorial boards for several journals in his field.
Dr. McClung is widely known as an educator, translating clinical research information into practical strategies of evaluation and treatment for other physicians. He is an active member of multiple international societies focusing on bone diseases and their treatment. He serves as a member of the Council of Scientific Advisors for the International Osteoporosis Foundation, on the Scientific Advisory Board of the National Osteoporosis Foundation, and as a medical advisor for the Paget Foundation. He was a member of the World Health Organization Fracture Risk Task Force that led to the development of the FRAX® tool. He is a member of the global advisory boards for multiple companies and organizations. He has served on the Endocrinology and Metabolism Advisory Committee of the FDA and has participated in the development of evidence–based guidelines for the treatment of osteoporosis for several national and international societies.